A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

NCT01313663 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer, Small Cell

Interventions

DRUG: pazopanib
DRUG: pemetrexed

Sponsor

GlaxoSmithKline